埃索美拉唑肠溶片联合理中丸治疗胃溃疡的临床研究

发布时间：2019-06-14 12:41

【摘要】：目的观察埃索美拉唑肠溶片联合理中丸治疗胃溃疡的临床疗效及安全性。方法将54例胃溃疡患者随机分为对照组27例和试验组27例。对照组口服埃索美拉唑镁肠溶片40 mg,tid;试验组在对照组治疗的基础上,口服理中丸9 g,bid。2组患者一个疗程均为7 d,连续治疗2个疗程。比较2组患者的临床疗效、血清白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF),碱性成纤维细胞生长因子(b FGF)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.59%(25/27例)和70.37%(19/27例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的血清IL-8分别为(15.85±2.08),(19.37±2.11)pg·m L~(-1);TNF-α分别为(70.75±10.05),(82.65±11.03)pg·m L~(-1),差异均有统计学意义(均P0.05)。治疗后,试验组和对照组的VEGF分别为(473.54±50.78),(456.31±51.57)pg·m L~(-1);b FGF分别为(567.43±63.24),(540.86±58.67)pg·m L~(-1),差异均无统计学意义(均P0.05)。2组患者发生的药物不良反应主要有腹痛、恶心、皮疹。试验组和对照组的药物不良反应发生率为11.11%和18.52%,差异无统计学意义(P0.05)。结论埃索美拉唑肠溶片联合理中丸能够显著提高胃溃疡的临床疗效,且不增加药物不良反应的发生率。
[Abstract]:Objective To observe the clinical effect and safety of the combination of Esomeiramine enteric-coated tablets and the treatment of stomach ulceration. Methods 54 patients with gastric ulcer were randomly divided into control group (27 cases) and test group (27 cases). The control group was treated with Esomeiramine magnesium enteric-coated tablet 40 mg, tid, and the experimental group was treated by the control group. The treatment course was 7 days, and 2 courses were treated continuously. The clinical efficacy, serum interleukin-8 (IL-8), tumor necrosis factor-1 (TNF-1), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) level, and the occurrence of adverse drug reactions were compared in group 2 patients. Results The total effective rate of the test group and the control group was 92.59% (25/27) and 70.37% (19/27), respectively. After the treatment, the serum IL-8 in the test group and the control group were (15.85-2.08), (19.37-2.11) pg 路 m-L-(-1), respectively (70.75-10.05), (82.65-11.03) pg 路 m-L-(-1), and the difference was statistically significant (all P0.05). After the treatment, the VEGF of the test group and the control group were (473.54, 50.78), (456.31-51.57) pg 路 m-L-(-1), and b-FGF was (567.43-63.24), (540.86-58.67) pg 路 m-L-(-1), and there was no significant difference in the difference (P0.05). Rash. The incidence of adverse drug reactions in the test group and the control group was 11.11% and 18.52%, the difference was not significant (P0.05). Conclusion The combination of Esomeiramine enteric-coated tablet can significantly improve the clinical curative effect of the stomach ulceration without increasing the incidence of adverse drug reactions.
【作者单位】：南阳市中心医院消化内科;南昌大学医院临床医学;郑州人民医院血液透析科;
【基金】：河南省医学科技攻关计划基金资助项目(201004022)
【分类号】：R975

【参考文献】